CLAIMS

1. A solid oral pharmaceutical composition comprising:

200 mg of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) Form I and

a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2) and a polymer,

wherein the substantially amorphous Compound 2 is present in the solid oral pharmaceutical composition in an amount of 125 mg,

wherein Compound 1 Form I is characterized by one or more peaks at 15.4, 16.3, and 14.5 degrees in an X-ray powder diffraction pattern,

wherein substantially amorphous Compound 2 has less than 15% crystallinity, and

wherein the solid oral pharmaceutical composition is a tablet comprising 25 to 50 percent by weight Compound 1 Form I, and 15 to 35 percent weight of a solid dispersion comprising Compound 2.

2. The solid oral pharmaceutical composition of claim 1 further comprising:

a. a filler;

b. a disintegrant;

c. a surfactant; and

d. a binder;

referred to as **PC-I**.

3. The solid oral pharmaceutical composition of claim 2, further comprising:

e. a lubricant

referred to as **PC-III**.

4. The solid oral pharmaceutical composition of claim 1, wherein the solid oral pharmaceutical composition further comprises:

a filler which is microcystalline cellulose in an amount from 20 to 30 percent by weight,

a disintegrant which is croscarmelose sodium in an amount from 3 to 10 percent by weight,

a surfactant which is sodium lauryl sulfate in an amount from 0.5 to 2 percent by weight,

a binder which is polyvinylpyrrolidone in an amount from 0 to 5 percent by weight, and

a lubricant which is magnesium stearate, in an amount from 0.5 to 2 percent by weight.

5. The solid oral pharmaceutical composition of claim 1, comprising 30 to 50 percent by weight Compound 1 Form I.

6. The solid oral pharmaceutical composition of any of claims 1-4 having the following formulation:

	% by wgt.
Compound 1 Form I	25-50
A solid dispersion comprising substantially amorphous Compound 2	15-35
Microcrystalline cellulose	20-30
Croscarmellose sodium	3-10
Sodium lauryl sulfate	0.5-2
Polyvinylpyrrolidone	0-5
Magnesium stearate	0.5-2

referred to as **PC-IV**.

7. The solid oral pharmaceutical composition of any of claims 1-6, further comprising a colorant and a wax.

8. The tablet of any of claims 1-7 having the following formulation:

	% by wgt.
Compound 1 Form I	35
Solid dispersion comprising substantially amorphous Compound 2	28
Microcrystalline cellulose	26
Croscarmellose sodium	6
Sodium lauryl sulfate	1
Polyvinylpyrrolidone	3
Magnesium stearate	1

referred to as **PC-VIII**, or:

	% by wgt.
Compound 1 Form I	31
Solid dispersion comprising substantially amorphous Compound 2	32
Microcrystalline cellulose	26
Croscarmellose sodium	6
Sodium lauryl sulfate	1
Polyvinylpyrrolidone	3
Magnesium stearate	1

referred to as **PC-IX**,

or:

	mg
Compound 1 Form I	200
Solid dispersion comprising substantially amorphous Compound 2	156
Microcrystalline cellulose	150
Croscarmellose sodium	34
Sodium lauryl sulfate	4
Polyvinylpyrrolidone	15
Magnesium stearate	6

referred to as **PC-XI**, or:

	% by wgt.
Compound 1 Form I	34
Solid dispersion comprising substantially amorphous Compound 2	27
Microcrystalline cellulose	25
Croscarmellose sodium	6
Sodium lauryl sulfate	1
Polyvinylpyrrolidone	3
Magnesium stearate	1
Colorant	3

referred to as **PC-XIV**, or:

	% by wgt.
Compound 1 Form I	30
Solid dispersion comprising substantially amorphous Compound 2	31
Microcrystalline cellulose	25
Croscarmellose sodium	6
Sodium lauryl sulfate	1
Polyvinylpyrrolidone	3
Magnesium stearate	1
Colorant	3

referred to as **PC-XV**, or:

	mg
Compound 1 Form I	200
Solid dispersion comprising substantially amorphous Compound 2	156
Microcrystalline cellulose	150
Croscarmellose sodium	34
Sodium lauryl sulfate	4
Polyvinylpyrrolidone	15
Magnesium stearate	6
Colorant	17

referred to as **PC-XVII**.

9. A solid oral pharmaceutical composition comprising:

100 mg of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) Form I and

a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2) and a polymer,

wherein the substantially amorphous Compound 2 is present in the solid oral pharmaceutical composition in an amount of 125 mg,

wherein Compound 1 Form I is characterized by one or more peaks at 15.4, 16.3, and 14.5 degrees in an X-ray powder diffraction pattern,

wherein substantially amorphous Compound 2 has less than 15% crystallinity,

and wherein the solid oral pharmaceutical composition is a tablet having the following formulation:

Component	mg/Tablet
Compound 1 Form I	100
Solid dispersion comprising substantially amorphous Compound 2	156
Microcrystalline cellulose	55
Croscarmellose sodium	7
Polyvinylpyrrolidone	11
Sodium lauryl sulfate	3
Total Granules	332
Croscarmellose sodium	18
Microcrystalline cellulose	53
Magnesium stearate	4
Total Tablet	407

referred to as **PC-XXIII**.

10. The tablet of any of claims 1-7 having the following formulation:

	mg
Compound 1 Form I	200

Substantially amorphous Compound 2	125
Microcrystalline cellulose	150
Croscarmellose sodium	34
Sodium lauryl sulfate	4
Polyvinylpyrrolidone	15
Magnesium stearate	6
Colorant	17

referred to as **PC-XVIII**.

11. A method of preparing a tablet according to any one of claims 1-9, wherein the method comprises:

a) wet granulating the following components to produce a granule:

a. Compound 1 Form I;

b. a solid dispersion comprising substantially amorphous Compound 2;

c. a filler;

d. a disintegrant;

e. a surfactant; and

f. a binder;

and

b) compressing the following components to produce a tablet:

i. a plurality of granules from step a);

ii) a disintegrant;

iii) a filler; and

iv) a lubricant,

wherein Compound 1 Form I is characterized by one or more peaks at 15.4, 16.3, and 14.5 degrees in an X-ray powder diffraction pattern, and

wherein substantially amorphous Compound 2 has less than 15% crystallinity.

12. A kit comprising the solid oral pharmaceutical composition of claim 1 and a separate therapeutic agent.

13. The kit of claim 12, wherein the solid oral pharmaceutical composition and the therapeutic agent are in separate containers.

14. The kit of claim 13, wherein the containers are bottles, vials, or blister packs, or combination thereof.